Scarica l'app Stockscreener
0.4836
7.55%
-0.0395
Pre-mercato:
.48
-0.0036
-0.74%
Precedente Chiudi:
$0.5231
Aprire:
$0.523
Volume 24 ore:
5.90M
Relative Volume:
0.20
Capitalizzazione di mercato:
$29.25M
Reddito:
-
Utile/perdita netta:
$-12.89M
Rapporto P/E:
-0.1911
EPS:
-2.53
Flusso di cassa netto:
$-11.95M
1 W Prestazione:
-15.81%
1M Prestazione:
+30.17%
6M Prestazione:
-59.70%
1 anno Prestazione:
-68.80%
Intervallo 1D:
$0.4528
$0.53
Intervallo di 1 settimana:
$0.4528
$0.649
Portata 52W:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Confronta PSTV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.4836 | 32.43M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics Inc. Added to Custom Quant Screener Today2025 Growth vs Value & Consistent Return Strategy Ideas - beatles.ru
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases - MarketScreener
Plus Therapeutics shares rise 2.61% premarket after reporting stockholders' equity of $3 million, satisfying Nasdaq Listing Rule. - AInvest
How Plus Therapeutics Inc. stock performs during market volatilityVolume Spike & Fast Entry High Yield Tips - beatles.ru
Plus Therapeutics presents positive Respect-LM trial results of Reyobiq in leptomeningeal metastases - MarketScreener
Plus Therapeutics price target lowered to $3 from $4 at Maxim - TipRanks
Plus Therapeutics presents results from ReSPECT-LM Phase 1 trial - TipRanks
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics Reports Promising Efficacy and Safety Data for REYOBIQ in Leptomeningeal Metastases Clinical Trial - Quiver Quantitative
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases - GlobeNewswire
87% Clinical Response: Plus Therapeutics' REYOBIQ Breakthrough Shows Promise for Terminal Brain Cancer Patients - Stock Titan
Why Did Plus Therapeutics Plunge 17.83% After Earnings? - AInvest
Plus Therapeutics Misses on Revenue and Costs: Earnings Drag Stock and Signal Weak Short-Term Prospects - AInvest
Plus Therapeutics Q2 Earnings Miss Sparks Mixed Market Reaction - AInvest
What is Plus Therapeutics Inc. s P E ratio telling us2025 Momentum Check & Verified Technical Trade Signals - classian.co.kr
Why Plus Therapeutics Inc. stock attracts strong analyst attention2025 Market WrapUp & Technical Entry and Exit Tips - thegnnews.com
Plus Therapeutics announces $1.6 million advance payment from CPRIT - MSN
Plus Therapeutics Posts Q2 2025 Loss as Revenue Falls Short, Sparking Mixed Market Reactions - AInvest
Will Plus Therapeutics Inc. Recover After Recent Decline2025 Institutional Moves & Real-Time Volume Analysis Alerts - newsyoung.net
Optimistic Buy Rating for Plus Therapeutics Driven by Strategic Financial Positioning and Clinical Advancements - TipRanks
Plus Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Plus Therapeutics Approves Key Proposals at Annual Meeting - MSN
Biotech Valuation Dilemmas: Can Plus Therapeutics (PSTV) Navigate the Grant-to-Product Transition? - AInvest
Assessing Plus Therapeutics (PSTV) as a High-Risk, High-Reward Play in CNS Oncology Innovation - AInvest
Plus Therapeutics Reports Stockholders’ Equity in Excess of - GlobeNewswire
Plus Therapeutics' Nasdaq Compliance Victory: A Strategic Win in the High-Growth CNS Oncology Sector - AInvest
Unlocking the Value of Plus Therapeutics: A Strategic Buy Case Amid Clinical Breakthroughs and Undervaluation - AInvest
Plus Therapeutics shares fall 12.42% after-hours following a new issue of shares. - AInvest
The Oncology Institute, Inc. shares rise 1.06% after-hours following Plus Therapeutics' positive CNSide CSF Assay data presentation. - AInvest
Plus Therapeutics Maintains Buy Rating with $3.00 Price Target - AInvest
Colorectal Cancer Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma, Shanghai Henlius - Barchart.com
Plus Therapeutics Reports $3M in Stock Equity - Baystreet.ca
Plus Therapeutics (PSTV) Falls After Mixed Q2 Results and Secondary Offering - GuruFocus
Plus Therapeutics meets Nasdaq equity requirement to maintain listing By Investing.com - Investing.com Nigeria
Plus Therapeutics meets Nasdaq equity requirement to maintain listing - Investing.com
Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements | PSTV Stock News - GuruFocus
Plus Therapeutics Reports Satisfactory Equity, Avoids Nasdaq Delisting - AInvest
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - MarketScreener
$3M Equity Achievement: Plus Therapeutics CNS Cancer Drug Developer Maintains Nasdaq Listing Status - Stock Titan
Buy Rating for Plus Therapeutics: Strategic Market Launch and Promising Financial Outlook - TipRanks
We're Keeping An Eye On Plus Therapeutics' (NASDAQ:PSTV) Cash Burn Rate - Yahoo Finance
Plus Therapeutics 2025 Q2 Earnings Remarkable Turnaround in Net Income - AInvest
Plus: Q2 Earnings Snapshot - Norwalk Hour
Plus Therapeutics Posts Q2 Profit Jump - AOL.com
Plus Therapeutics Reports Strong Q2 2025 Results - TipRanks
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates - MSN
Plus Therapeutics Posts Q2 Profit Jump, Reversing Last Year's Loss - AInvest
Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Plus Therapeutics Awaits Nasdaq Compliance Confirmation - TipRanks
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - The Manila Times
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Plus Therapeutics Inc Azioni (PSTV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 13 '24 |
Buy |
1.50 |
4,000 |
5,996 |
15,188 |
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):